Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

Abstract Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitating drug combination therapeutic approaches. Using...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Perla Pucci, Liam C. Lee, Miaojun Han, Jamie D. Matthews, Leila Jahangiri, Michaela Schlederer, Eleanor Manners, Annabel Sorby-Adams, Joshua Kaggie, Ricky M. Trigg, Christopher Steel, Lucy Hare, Emily R. James, Nina Prokoph, Stephen P. Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, G. A. Amos Burke, Suzanne D. Turner
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2024-04-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-024-47771-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!